Back to top
more

Ligand Pharmaceuticals (LGND)

(Delayed Data from NSDQ)

$115.45 USD

115.45
135,153

-6.63 (-5.43%)

Updated Nov 14, 2024 04:00 PM ET

After-Market: $115.48 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Gourav Kanti Bagchi headshot

Pick These 5 Profitable Stocks With Impressive Returns

by Gourav Kanti Bagchi

Profitability analysis helps in calculating the total expenses borne and total revenues generated by a company

    Vertex's Cystic Fibrosis Drug Gets FDA Nod for Children

    by Zacks Equity Research

    Vertex's (VRTX) cystic fibrosis drug, Kalydeco gets FDA approval to treat children aged 12 months to two years

      Aniruddha Ganguly headshot

      5 Sizzling Stocks Played Down by Hedge Funds in Q2

      by Aniruddha Ganguly

      We pick five large cap top-ranked stocks that have been ignored by hedge funds in Q2.

        Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech

        by Zacks Equity Research

        Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.

          Ligand (LGND) Beats on Q2 Earnings & Revenues, Raises View

          by Zacks Equity Research

          Ligand (LGND) beats both earnings and sales estimates in the second quarter of 2018. The company raised its guidance for 2018.

            Ligand Pharmaceuticals (LGND) Q2 Earnings and Revenues Beat Estimates

            by Zacks Equity Research

            Ligand (LGND) delivered earnings and revenue surprises of 178.49% and 48.94%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

              What Lies in Store for Ligand (LGND) This Earnings Season?

              by Zacks Equity Research

              Ligand's (LGND) Captisol formulation technology is expected to drive milestone and royalty payments in second-quarter 2018.

                REGN vs. LGND: Which Stock Should Value Investors Buy Now?

                by Zacks Equity Research

                REGN vs. LGND: Which Stock Is the Better Value Option?

                  HZNP vs. LGND: Which Stock Is the Better Value Option?

                  by Zacks Equity Research

                  HZNP vs. LGND: Which Stock Is the Better Value Option?

                    3 Biotech Stocks Up in the Past Month on Industry Turnaround

                    by Zacks Equity Research

                    We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after declining in the initial four months of the year.

                      The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals

                      by Zacks Equity Research

                      The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals

                        Kitov (KTOV) Gets Approval from FDA for Consensi, Shares Up

                        by Zacks Equity Research

                        Kitov Pharma (KTOV) gained as the FDA approved Consensi (amlodipine and celecoxib) oral tablets for the treatment of osteoarthritis pain and hypertension.

                          Gourav Kanti Bagchi headshot

                          "Right To Try" Brings Good News for Biotech Sector: 5 Picks

                          by Gourav Kanti Bagchi

                          Passage of the Right To Try law and WHO's focus on assessing the quality of bio-similar drugs is expected to benefit biotech stocks.

                            Catalyst's Fridapse Gets Priority Review by FDA, Shares Up

                            by Zacks Equity Research

                            The FDA grants Priority Review to Catalyst's (CPRX) lead pipeline candidate, Firdapse, and set an action date of Nov 28, 2018.

                              Allergan Recalls Taytulla Oral Contraceptives, Stock Down

                              by Zacks Equity Research

                              Allergan (AGN) recalls some sample packs of Taytulla oral birth control pills. Shares decline.

                                Bayer's Generic Competition, Pipeline Setback Issues Remain

                                by Zacks Equity Research

                                Generic threats/competition for many of its products remain a concern for Bayer (BAYRY).

                                  Prothena Restructures Resources, to Cut Workforce by 57%

                                  by Zacks Equity Research

                                  Prothena announces a reduction in workforce by 57%, due to the discontinuation of lead program, NEOD001.

                                    AbbVie's Imbruvica's Phase III Study Meets Primary Endpoint

                                    by Zacks Equity Research

                                    AbbVie's (ABBV) phase III iLLUMINA study evaluating Imbruvica in combination with Gazyva meets its primary endpoint of improvement in progression-free survival.

                                      Agios (AGIO) Progressing Well on Pipeline Amid Competition

                                      by Zacks Equity Research

                                      Agios (AGIO) has several interesting candidates in its pipeline. However, the company still faces stiff competition.

                                        SWTUY or LGND: Which Is the Better Value Stock Right Now?

                                        by Zacks Equity Research

                                        SWTUY vs. LGND: Which Stock Is the Better Value Option?

                                          Dr. Reddy's (RDY) Q4 Earnings Fall, Revenues Decline Y/Y

                                          by Zacks Equity Research

                                          Dr. Reddy's bottom line and top line suffered a year-over-year decline, in the fourth quarter of fiscal 2018.

                                            Allergan Stock Down Since Q1 Earnings Report: Here's Why

                                            by Zacks Equity Research

                                            Though Allergan (AGN) boasts a solid underlying business, its stock is down. Here we discuss why.

                                              Inovio Initiates Phase II Study on Pipeline Drug VGX-3100

                                              by Zacks Equity Research

                                              Inovio (INO) begins a phase II study to evaluate the efficacy of its pipeline candidate VGX-3100 on adult men and women with human papilloma virus (HPV)-related anal dysplasia.

                                                AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia

                                                by Zacks Equity Research

                                                AstraZeneca's (AZN) Lokelma secures an FDA approval for the treatment of hyperkalemia in adults.

                                                  Ligand Pharmaceuticals (LGND) Hits a 52-Week High, Can the Run Continue?

                                                  by Zacks Equity Research

                                                  Ligand Pharmaceuticals Incorporated is at a 52-week high, but can investors hope for more gains in the future? We take a look at the fundamentals for LGND for clues.